SOURCE: Addison-Davis Diagnostics, Inc.

September 13, 2005 12:30 ET

Addison-Davis Secures $750,000 in Financing

WESTLAKE VILLAGE, CA -- (MARKET WIRE) -- September 13, 2005 -- Addison-Davis Diagnostics, Inc. (OTC BB: ADDI) is pleased to announce that they have secured $750,000 in financing. The Company has concluded negotiations and terms are to be released upon closing. The Company expects the financing to close the week ending September 16, 2005.

"The present financing will allow Addison-Davis to execute its awareness campaign of its new Parents' Tool Drug Test Program," stated Edward W. Withrow III, CEO of Addison-Davis.

The "Parents Tool" Drug Test, a self-contained NIDA (National Institute of Drug Abuse) 5-panel drug test, will be marketed by national retail chains throughout the United States. The "Parents Tool" drug test will screen for Amphetamines (Crystal Meth), Cocaine, Opiates, Phencyclidine (PCP) and Marijuana (THC).

About Addison-Davis

Addison-Davis Diagnostics, Inc. is responding to industry demands by supplying quick response diagnostic tests that are user friendly, produce fast simple results and are less costly, less problematic and less time consuming. Addison-Davis is currently focused on bringing fast and reliable "Point-of-care" Diagnostic Testing through the use of its patented technology to Healthcare Professionals, Hospitals, certain branches of the Government and the Workplace environment for drugs-of-abuse and medical conditions and diseases.

For more information please visit our website www.addisondavis.com or contact Matt Maguire 1-866 THE APPL(E)

Safe Harbor

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

Contact Information

  • Contact:
    Matt Maguire
    1-866 THE APPL(E)